EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

Stage 2: Which supply routes deserve further evaluation?

Dose Diligence research deskSection 12 · Page 3 of 11Last updated 17 Nov 2026

Screen the exact arrangement before scoring suppliers. Do not assign an organisation a blanket “approved supplier” status that carries across products, facilities and states.

What regulatory facts should the buyer refresh?

FDA’s April 1, 2026 reminder states that semaglutide and tirzepatide are not on its shortage list or 503B bulks list. It describes restrictions on outsourcing facilities using bulk drug substances. Recheck the relevant product and presentation in FDA’s live shortage database at approval and contracting. (fda.gov)

For 503A arrangements, a patient-specific prescription does not eliminate restrictions on essentially copying commercially available products. FDA also explains that adding vitamin B12 does not automatically avoid those restrictions; the applicable analysis includes documented prescriber determinations about a significant difference for an identified patient. (fda.gov)

The Fifth Circuit’s semaglutide opinion, issued August 27 and revised September 1, 2026, affirmed the district court judgment upholding FDA’s delisting action. Counsel should check subsequent docket activity rather than rely on a supplier’s description of pending litigation. (ca5.uscourts.gov)

FDA separately announced a proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list on April 30, 2026. A proposal is not a final determination: this research did not verify a subsequent final action. (fda.gov)

Route-screen checklist

Proposed arrangementQuestions to resolve before commercial ranking
Approved medicine purchased as clinic stockIs the account eligible for the exact product? What permissions, storage arrangements, traceability responsibilities and intended-use restrictions apply?
Approved medicine dispensed to patientsWhich legal entity and facility dispense? Which patients, products, states and payment routes are accepted?
Manufacturer-linked patient accessWhat must the prescriber submit? What must the patient complete? Who handles payment, fulfilment, support and refills?
Proposed compounded preparationWhat is the precise formulation, starting material, facility and statutory pathway? Which requirements and restrictions apply to this preparation and intended arrangement?

For branded-access comparison, LillyDirect’s provider FAQ describes prescription submission and pharmacy-managed refill processes. NovoCare’s provider page describes electronic prescribing, patient payment and home delivery. Evaluate these as patient-access workflows; those pages are not evidence that your clinic has a wholesale purchasing account. (lilly.com)

For an organisation serving Medicare beneficiaries, add a separate coverage branch rather than assuming every patient belongs in a self-pay workflow. CMS publishes pharmacy-specific eligibility, product and processing information for the Medicare GLP-1 Bridge. (cms.gov)

Hold point: do not advance an unresolved compounded route into a recommended savings shortlist. Obtain product-specific clinical and legal review first. FDA registration itself does not establish product approval or lawful marketing. (fda.gov)

Explore the table row by row

A working view of the research

Approved medicine purchased as clinic stock

Questions to resolve before commercial ranking
Is the account eligible for the exact product? What permissions, storage arrangements, traceability responsibilities and intended-use restrictions apply?

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. ca5.uscourts.gov · Source 2 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  3. fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  4. lilly.com · Source 4 ↗https://www.lilly.com/lillydirect/hcp/faq
  5. cms.gov · Source 5 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
  6. fda.gov · Source 6 ↗https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
Section sources →